Mabwell (Shanghai) Bioscience Co., Ltd. Sustainability Profile
Mabwell (Shanghai) Bioscience Co., Ltd., a leading biopharmaceutical company based in China, is renowned for its innovative contributions to the biotechnology sector. Founded in 2016, Mabwell has rapidly established itself as a key player in the development of monoclonal antibodies and other biologics, focusing on therapeutic solutions for oncology and autoimmune diseases. Headquartered in Shanghai, Mabwell operates extensively across major regions in China and is expanding its global footprint. The company’s core offerings include cutting-edge antibody drugs and advanced drug delivery systems, distinguished by their high specificity and efficacy. Mabwell's commitment to research and development has led to significant milestones, including successful collaborations and partnerships that enhance its market position. With a strong emphasis on quality and innovation, Mabwell continues to drive advancements in the biopharmaceutical industry.
DitchCarbon Score
How does Mabwell (Shanghai) Bioscience Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mabwell (Shanghai) Bioscience Co., Ltd.'s score of 22 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mabwell (Shanghai) Bioscience Co., Ltd.'s reported carbon emissions
Mabwell (Shanghai) Bioscience Co., Ltd., headquartered in China, currently does not report any specific carbon emissions data for the most recent year, as no emissions figures are available. The company has not established documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As of now, Mabwell's climate commitments and initiatives remain unspecified, indicating a potential area for development in their sustainability strategy. The absence of emissions data and reduction targets suggests that the company may be in the early stages of addressing its carbon footprint and climate impact. Given the increasing importance of climate action in the bioscience industry, Mabwell may benefit from setting measurable targets and engaging in initiatives that align with global sustainability goals.
How Carbon Intensive is Mabwell (Shanghai) Bioscience Co., Ltd.'s Industry?
How Carbon Intensive is Mabwell (Shanghai) Bioscience Co., Ltd.'s Location?
Mabwell (Shanghai) Bioscience Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mabwell (Shanghai) Bioscience Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
